Acromegaly Market Drivers That Will Shape the Next Decade: Insights from Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Acromegaly Market Size By 2025?
Markedly expanding over the past few years, the market associated with acromegaly is set for continued ascent, poised to climb from a value of $2.15 billion in 2024 to reach $2.56 billion the following year, reflecting a robust compound annual growth rate of 19.3%; this upward trajectory observed during the historical period is primarily fueled by a rise in the availability of acromegaly therapies, enhanced public and professional recognition of the condition, supportive government programs, and a strong requirement for efficacious medical interventions.

How Big Is the Acromegaly Market Size Expected to Grow by 2029?
Anticipation surrounds the acromegaly sector, which is projected to expand quickly over the coming years, reaching a valuation of $4.93 billion by 2029, fueled by a compound annual growth rate (CAGR) of 17.8%; this surge during the projection timeframe is primarily driven by escalating research and development investments aimed at novel acromegaly interventions, the proliferation of screening initiatives, increasing expenditure in healthcare services, and a heightened preference for less invasive therapeutic approaches. Contemporary shifts shaping this market involve the emergence of pioneering acromegaly treatments, progress in designing therapies specifically targeting the condition, a robust assortment of pharmaceuticals awaiting approval, various improvements in existing treatment modalities, and the maturation of personalized medical strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Key Market Drivers Powering Acromegaly Market Expansion and Growth?
The projected rise in conditions like diabetes, which fall under the umbrella of hormonal ailments, is anticipated to fuel the expansion of the acromegaly market moving ahead. Endocrine disorders, as these ailments are also termed, stem from disturbances within the body's endocrine system; diabetes stands out as a particularly widespread and major example. Both acromegaly and various other endocrine issues can originate from the excessive secretion of hormones, such as cortisol or growth hormone. Furthermore, the elevated levels of growth hormone negatively influence insulin production, leading to approximately half of acromegaly patients experiencing either insulin resistance or the development of type 2 diabetes mellitus. To illustrate this trend, data from the UK's Office for Health Improvement and Disparities in March 2024 indicated that across the period spanning March 2022 to March 2023, there was a 22% uptick in type 1 diabetes sufferers receiving all eight necessary care components, and a 21% rise for type 2 diabetes patients, with the proportion reaching target HbA1c levels climbing to an all-time high of 37.9% as recorded by the National Diabetes Audit (NDA). Consequently, the increasing prevalence of hormonal diseases serves as a stimulus for the acromegaly market's advancement.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Acromegaly Market?
Leading corporations within the acromegaly sector are concentrating their efforts on formulating novel offerings and approaches, exemplified by generic lanreotide, with the aim of advancing therapeutic choices and yielding better health results for those afflicted. This non-branded version of the drug, employed in managing acromegaly and specific neuroendocrine neoplasms, functions as a somatostatin analog, thereby diminishing the secretion of growth hormone and broadening availability of efficacious treatment modalities. A concrete illustration of this movement is the October 2024 introduction in the United States by Teva Pharmaceutical Industries Ltd., an Israeli firm specializing in generic pharmaceuticals, of the inaugural and sole generic equivalent to Sandostatin LAR Depot; this injectable suspension, active ingredient octreotide acetate, is specifically approved for treating acromegaly alongside debilitating diarrhea linked to carcinoid syndrome, marking an expansion of vital care access for individuals needing such medical interventions.

What Are the Emerging Segments in the Acromegaly Market?
The acromegalymarket covered in this report is segmented -

1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly; Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess; Secondary Growth Hormone Excess

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Who Are the Global Leaders in the Acromegaly Market?
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Which are the Top Profitable Regional Markets for the Acromegaly Industry?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.